SBH
KNSA icon

Segall Bryant & Hamill’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Segall Bryant & Hamill’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.6M Buy
+71,901
New +$3.73M 0.05% 328
2024
Q4 		– Sell
-27,026
Closed -$675K – 612
2024
Q3 		$675K Buy
+27,026
New +$658K 0.01% 534

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Segall Bryant & Hamill's KNSA Position: Q2 2026 in Review

Segall Bryant & Hamill opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 71,901 shares worth $4.6M. The stake represents 0.05% of the portfolio and ranks #328 among its holdings. This is a return to the name: Segall Bryant & Hamill previously reported a position in KNSA as recently as Q3 2024.

Segall Bryant & Hamill first reported a position in KNSA in Q3 2024 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Segall Bryant & Hamill held 71,901 shares of Kiniksa Pharmaceuticals worth $4.6M as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Segall Bryant & Hamill position in Q2 2026.
  • Kiniksa Pharmaceuticals made up 0.05% of Segall Bryant & Hamill's portfolio in Q2 2026, its #328 holding.
  • Segall Bryant & Hamill first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.